Thrombolytic therapies: The current state of affairs

Journal of Endovascular Therapy

Volumn 12, Issue 2, 2005, Pages 224-232

  Perler, Bruce ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Acute peripheral arterial occlusions; Cerebrovascular accident; Deep venous thrombosis; Fibrinogen; Myocardial infarction; Plasmin; Plasminogen; Pulmonary embolism; Streptokinase; Thrombotic occlusive disease; Tissue plasminogen activator; Urokinase

Indexed keywords

ALTEPLASE; FIBRIN; HEPARIN; PLASMIN; PLASMINOGEN; PROUROKINASE; RETEPLASE; STREPTOKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UROKINASE; WARFARIN;

ACUTE HEART INFARCTION; ARTERY OCCLUSION; BLEEDING; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG COST; DRUG MECHANISM; DRUG SAFETY; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; REVIEW; THROMBOSIS;

ARTERIAL OCCLUSIVE DISEASES; CEREBROVASCULAR ACCIDENT; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; PULMONARY EMBOLISM; VENOUS THROMBOSIS;

EID: 17144397176     PISSN: 15266028     EISSN: None     Source Type: Journal    
DOI: 10.1583/04-1438.1     Document Type: Review

References (53)

1. Semba CP, Bakal CW, Calis KA, et al. Alteplase as an alternative to urokinase. Advisory Panel on Catheter-Directed Thrombolytic Therapy. J Vasc Interv Radiol. 2000;11:279-287.
2. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673-682.
3. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico. GISSI-2: a factorial randomised trial of alteplase versus streptokinase and heparin versus no heparin among 12,490 patients with acute myocardial infarction. Lancet. 1990;336:65-71.
4. Third International Study of Infarct Survival Collaborative Group. ISIS-3: a randomized comparison of streptokinase versus tissue plasminogen activator versus anistreplase and of aspirin plus heparin versus aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753-770.
5. Weitz JI. Limited fibrin specificity of tissue-type plasminogen activator and its potential link to bleeding. J Vasc Interv Radiol. 1995;6:19S-23S.
6. Gurewich V. Fibrinolysis: an unfinished agenda. Blood Coagul Fibrinolysis. 2000;11:401-408.
7. Schafer K, Konstantinides S, Riedel C, et al. Different mechanisms of increased luminal stenosis after arterial injury in mice deficient for urokinase or tissue-type plasminogen activator. Circulation. 2002;106:1847-1852.
8. National Center for Chronic Disease Prevention and Health Promotion fact sheet. Actual causes of death in the United States, 2000. Available at http://www.cdc.gov/nccdphp/factsheets/death. causes2000.htm. Accessed March 29, 2004.
9. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients. Lancet. 1994;343:311-322.
10. Ohman EM, Harrington RA, Cannon CP, et al. Intravenous thrombolysis in acute myocardial infarction: sixth ACCP consensus conference on antithrombotic therapy. Chest. 2001;119:253S-277S.
11. Collins R, Peto R, Baigent C, et al. Aspirin, heparin, and fibrinolytic therapy in suspected acute myocardial infarction. N Engl J Med. 1997;336:847-860.
12. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332:1418-1424.
13. The Continuous Infusion Versus Double-Bolus Administration of Alteplase (COBALT) Investigators. A comparison of continuous infusion of alteplase with double-bolus administration for acute myocardial infarction. N Engl J Med. 1997;337:1124-1130.
14. The Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators. A comparison of reteplase with alteplase for acute myocardial infarction. N Engl J Med. 1997;337:1118-1123.
15. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet. 1999;354:716-722.
16. International Joint Efficacy Comparison of Thrombolytics (INJECT) Investigators. Randomised, double-blind comparison of reteplase double-bolus administration with streptokinase in acute myocardial infarction (INJECT): trial to investigate equivalence. Lancet. 1995;346:329-336.
17. Dundar Y, Hill R, Dickson R, et al. Comparative efficacy of thrombolytics in acute myocardial infarction: a systematic review. QJM. 2003;96:103-113.
18. Neuhaus KL, Tebbe U, Gottwik M, et al. Intravenous recombinant tissue plasminogen activator (rt-PA) and urokinase in acute myocardial infarction: results of the German Activator Urokinase Study (GAUS). J Am Coll Cardiol. 1988;12:581-587.
19. GUSTO Angiographic Investigators. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. N Engl J Med. 1993;329:1615-1622.
20. Eikelboom JW, Mehta SR, Pogue J, et al. Safety outcomes in meta-analyses of phase 2 versus phase 3 randomized trials: intracranial hemorrhage in trials of bolus thrombolytic therapy. JAMA. 2001;285:444-450.
21. Gurwitz JH, Goldberg RJ, Chen Z, et al. Recent trends in hospital mortality of acute myocardial infarction- the Worcester Heart Attack Study. Have improvements been realized for all age groups? Arch Intern Med. 1994;154:2202-2208.
22. Aversano T, Aversano L, Passamani E, et al. Thrombolytic therapy versus primary percutaneous coronary intervention for myocardial infarction in patients presenting to hospitals without on-site cardiac surgery: a randomized controlled trial. JAMA. 2002;287:1943-1951.
23. Dalen JE. Pulmonary embolism: what have we learned since Virchow? Natural history, pathophysiology, and diagnosis. Chest. 2002;122:1440-1456.
24. McLachlin J, Paterson JC. Some basic observations on venous thrombosis and pulmonary embolism. Surg Gynecol Obstet. 1951;93:1-8.
25. Konstantinides S, Geibel A, Kasper W. Submassive and massive pulmonary embolism: a target for thrombolytic therapy? Thromb Haemost. 1999;82(Suppl 1):104-108.
26. Dalen JE, Alpert JS, Hirsch J. Thrombolytic therapy for pulmonary embolism: is it effective? Is it safe? When is it indicated? Arch Intern Med. 1997;157:2550-2556.
27. Konstantinides S, Geibel A, Olschewski M, et al. Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism: results of a multicenter registry. Circulation. 1997;96:882-888.
28. Urokinase-streptokinase embolism trial. Phase 2 results. A cooperative study. JAMA. 1974;229:1606-1613.
29. Goldhaber SZ, Kessler CM, Heit J, et al. Randomised controlled trial of recombinant tissue plasminogen activator versus urokinase in the treatment of pulmonary embolism. Lancet. 1988;2:293-298.
30. Goldhaber SZ, Kessler CM, Heit JA, et al. Recombinant tissue plasminogen activator versus a novel dosing regimen of urokinase in acute pulmonary embolism: a randomized controlled multicenter trial. J Am Coll Cardiol. 1992;20:24-30.
31. Meyer G, Sors H, Charbonnier B, et al. Effects of intravenous urokinase versus alteplase on total pulmonary resistance in acute massive pulmonary embolism: a European multicenter double-blind trial. J Am Coll Cardiol. 1992;19:239-245.
32. Arcasoy SM, Kreit JW. Thrombolytic therapy of pulmonary embolism: a comprehensive review of current evidence. Chest. 1999;115:1695-1707.
33. Kahn SR, Solymoss S, Lamping DL, et al. Long-term outcomes after deep vein thrombosis: postphlebitic syndrome and quality of life. J Gen Intern Med. 2000;15:425-429.
34. Mewissen MW, Seabrook GR, Meissner MH, et al. Catheter-directed thrombolysis for lower extremity deep venous thrombosis: report of a national multicenter registry. Radiology. 1999;211:39-49.
35. Kahn SR, Hirsch A, Shrier I. Effect of post-thrombotic syndrome on health-related quality of life after deep venous thrombosis. Arch Intern Med. 2002;162:1144-1148.
36. Meissner MH. Thrombolytic therapy for acute deep vein thrombosis and the venous registry. Rev Cardiovasc Med. 2002;3(Suppl 2):S53-S60.
37. Comerota AJ, Throm RC, Mathias SD, et al. Catheter-directed thrombolysis for iliofemoral deep venous thrombosis improves health-related quality of life. J Vasc Surg. 2000;32:130-137.
38. Semba CP, Dake MD. Iliofemoral deep venous thrombosis: aggressive therapy with catheter-directed thrombolysis. Radiology. 1994;191:487-494.
39. Ouriel K, Gray B, Clair D, et al. Complications associated with the use of urokinase and recombinant tissue plasminogen activator for catheter-directed peripheral arterial and venous thrombolysis. J Vasc Interv Radiol. 2000;11:295-298.
40. The STILE Investigators. Results of a prospective randomized trial evaluating surgery versus thrombolysis for ischemia of the lower extremity. The STILE trial. Ann Surg. 1994;220:251-268.
41. Razavi MK, Lee DS, Hofmann LV. Catheter-directed thrombolytic therapy for limb ischemia: current status and controversies. J Vasc Interv Radiol. 2004;15:13-23.
42. Ouriel K, Shortell CK, DeWeese JA, et al. A comparison of thrombolytic therapy with operative revascularization in the initial treatment of acute peripheral arterial ischemia. J Vasc Surg. 1994;19:1021-1030.
43. Mahler F for the Steering Committee, Study on Local Thrombolysis. Recombinant tissue plasminogen activator versus urokinase for local thrombolysis of femoropopliteal occlusions: a prospective, randomized multicenter trial. J Endovasc Ther. 2001;8:638-647.
44. Ouriel K, Kandarpa K. Safety of thrombolytic therapy with urokinase or recombinant tissue plasminogen activator for peripheral arterial occlusion: a comprehensive compilation of published work. J Endovasc Ther. 2004;11:436-446.
45. del Zoppo GJ. Antithrombotic treatments in acute ischemic stroke. Curr Opin Hematol, 2000;7:309-315.
46. National Institute of Neurological Disorders and Stroke rt-PA Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333:1581-1587.
47. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators. Lancet. 1998;352:1245-1251.
48. Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med. 1999;340:1781-1787.
49. Schriger DL, Kalafut M, Starkman S, et al. Cranial computed tomography interpretation in acute stroke: physician accuracy in determining eligibility for thrombolytic therapy. JAMA. 1998;279:1293-1297.
50. del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke. 1998;29:4-11.
51. Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. JAMA. 1999;282:2003-2011.
52. Ouriel K, Kaul AF, Leonard MC. Clinical and economic outcomes in thrombolytic treatment of peripheral arterial occlusive disease and deep venous thrombosis. J Vasc Surg. 2004;40:971-977.
53. Taylor TN, Davis PH, Torner JC, et al. Lifetime cost of stroke in the United States. Stroke. 1996;27:1459-1466.